230 related articles for article (PubMed ID: 11095436)
21. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
Portella G; Scala S; Vitagliano D; Vecchio G; Fusco A
J Clin Endocrinol Metab; 2002 Jun; 87(6):2525-31. PubMed ID: 12050209
[TBL] [Abstract][Full Text] [Related]
22. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
23. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
24. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.
Takeda T; Inaba H; Yamazaki M; Kyo S; Miyamoto T; Suzuki S; Ehara T; Kakizawa T; Hara M; DeGroot LJ; Hashizume K
J Clin Endocrinol Metab; 2003 Aug; 88(8):3531-8. PubMed ID: 12915632
[TBL] [Abstract][Full Text] [Related]
25. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.
Blagosklonny MV; Giannakakou P; Wojtowicz M; Romanova LY; Ain KB; Bates SE; Fojo T
J Clin Endocrinol Metab; 1998 Jul; 83(7):2516-22. PubMed ID: 9661637
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic potential of recombinant adenovirus expressing p53 in hepatocellular carcinoma cell lines].
Guo Y; Zeng Y; Wang K; Zhu X; Luo H; Zheng M; Li M; Chen J
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():43-5. PubMed ID: 11509137
[TBL] [Abstract][Full Text] [Related]
27. Determination of the optimal time for radioiodine therapy in anaplastic thyroid carcinoma using the adenovirus-mediated transfer of sodium iodide symporter gene.
So Y; Lee YJ; Lee WW; Chung JK
Oncol Rep; 2013 Apr; 29(4):1666-70. PubMed ID: 23404348
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.
Harris MP; Sutjipto S; Wills KN; Hancock W; Cornell D; Johnson DE; Gregory RJ; Shepard HM; Maneval DC
Cancer Gene Ther; 1996; 3(2):121-30. PubMed ID: 8729911
[TBL] [Abstract][Full Text] [Related]
29. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
31. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma.
Barzon L; Gnatta E; Castagliuolo I; Trevisan M; Moretti F; Pontecorvi A; Boscaro M; Palù G
Cancer Gene Ther; 2005 Apr; 12(4):381-8. PubMed ID: 15650765
[TBL] [Abstract][Full Text] [Related]
32. Restoration of p53 function in anaplastic Wilms' tumor.
Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
[TBL] [Abstract][Full Text] [Related]
33. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck.
Liu TJ; el-Naggar AK; McDonnell TJ; Steck KD; Wang M; Taylor DL; Clayman GL
Cancer Res; 1995 Jul; 55(14):3117-22. PubMed ID: 7606733
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
36. Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model.
Lee YJ; Chung JK; Kang JH; Jeong JM; Lee DS; Lee MC
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):235-41. PubMed ID: 19727716
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12.
Zhang R; DeGroot LJ
Endocrinology; 2003 Apr; 144(4):1393-8. PubMed ID: 12639922
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo.
Köck H; Harris MP; Anderson SC; Machemer T; Hancock W; Sutjipto S; Wills KN; Gregory RJ; Shepard HM; Westphal M; Maneval DC
Int J Cancer; 1996 Sep; 67(6):808-15. PubMed ID: 8824552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
